Daratumumab Market Trend

Daratumumab Market Daratumumab is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress. Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. In May 2016 daratumumab was also conditionally…